- Home
- ALXO vs ARCT Comparison
ALXO vs ARCT Comparison
Compare ALXO & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALXO | ARCT |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.9M | 198.1M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ALXO | ARCT |
|---|---|---|
| Price | $2.04 | $5.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | $3.50 | ★ $24.11 |
| AVG Volume (30 Days) | ★ 1.6M | 564.0K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.36 | 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,031,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.51 | $5.74 |
| 52 Week High | $2.66 | $24.14 |
Technical Indicators
Market Signals| Indicator | ALXO | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 53.04 | 26.97 |
| Support Level | $1.96 | N/A |
| Resistance Level | $2.31 | $7.98 |
| Average True Range (ATR) | 0.17 | 0.36 |
| MACD | -0.02 | -0.10 |
| Stochastic Oscillator | 28.43 | 0.23 |
Price Performance
Historical ComparisonAbout ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.